Clinical benefits of slowing the progression of renal failure

Kidney International

Volumn 68, Issue SUPPL. 99, 2005, Pages

  Locatelli, Francesco ^a   Del Vecchio, Lucia ^a   Pozzoni, Pietro ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

Anemia; Cardiovascular disease; Chronic kidney disease; Dislipidemia; End stage renal disease; Hyperphosphatemia; Hypertension; Proteinuria

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; CALCIUM PHOSPHATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; RAMIPRIL; ANTIHYPERTENSIVE AGENT; CALCIUM; PHOSPHATE;

ANEMIA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DIET THERAPY; DISEASE COURSE; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY INJURY; METABOLIC DISORDER; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROTEIN RESTRICTION; PROTEINURIA; RENAL PROTECTION; SMOKING CESSATION; BLOOD PRESSURE; CHRONIC DISEASE; DRUG EFFECT; DYSLIPIDEMIA; KIDNEY DISEASE; METABOLISM; PATHOPHYSIOLOGY; RENAL REPLACEMENT THERAPY; REVIEW; TIME;

ANEMIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DISEASE PROGRESSION; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; KIDNEY DISEASES; KIDNEY FAILURE; PHOSPHATES; PROTEINURIA; RENAL REPLACEMENT THERAPY; SMOKING CESSATION; TIME FACTORS;

EID: 33748288078     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.09927.x     Document Type: Conference Paper

References (41)

1. EGGERS PW, CONNERTON R, MCMULLAN M: The Medicare experience with end-stage renal disease: Trends in incidence, prevalence, and survival. Health Care Fin Rev 5:69-88, 1984
2. UNITED STATES RENAL DATA SYSTEM: USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2004
3. FOLEY RN, PARFREY PS, SARNAK MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 (Suppl 3):112-119, 1998
4. LOCATELLI F, MARCELLI D, CONTE F, et al: Patient selection affects end-stage renal disease outcome comparisons. Kidney Int 57(Suppl 74):S94-S99, 2000
5. KEITH DS, NICHOLS GA, GULLION CM, et al: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 164:659-663, 2004
6. LOCATELLI F, ALBERTI D, GRAZIANI G, et al: Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group. Lancet 337:1299-1304, 1991
7. KLAHR S, LEVEY AS, BECK GJ, et al: AND THE MODIfICATION OF DIET IN RENAL DISEASE STUDY GROUP: The effects of dietary protein restriction and blood pressure control on the progression of renal disease. N Engl J Med 330:877-884, 1994
8. LOCATELLI F, DEL VECCHIO L: How long can dialysis be postponed by low protein diet and ACE inhibitors? Nephrol Dial Transplant 14:1360-1364, 1999
9. SARNAK MJ, GREENE T, WANG X, et al: The effect of a lower target blood pressure on the progression of kidney disease: Long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 142:342-351, 2005
10. WRIGHT JT, JR., BAKRIS G, GREENE T, et al: African American Study of Kidney Disease and Hypertension Study Group: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288:2421-2431, 2002
11. LEWIS EJ, HUNSICKER LG, RAYMOND PB, ROHDE RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462, 1993
12. MASCHIO G, ALBERTI D, JANIN G, et al: Effect of the angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334:939-945, 1996
13. THE GISEN GROUP (GRUPPO ITALIANO DI STUDI EPIDEMIOLOGICI IN NEFROLOGIA): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857-1863, 1997
14. JAFAR TH, SCHMID CH, LANDA M, et al: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135:73-87, 2001
15. BRENNER BM, COOPER ME, DE ZEEUW D, et al: RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
16. LEWIS EJ, HUNSICKER LG, CLARKE WR, et al: COLLABORATIVE STUDY GROUP: Reno-protective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
17. RUGGENENTI P, PERNA A, LORIGA G, et al: REIN-2 Study Group: Blood-pressure control for renoprotection in patients with nondiabetic chronic renal disease (REIN-2): Multicentre, randomised controlled trial. Lancet 365:939-946, 2005
18. NAKAO N, YOSHIMURA A, MORITA H, et al: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 361:117-124, 2003
19. OWDA AK, et al: J Am Soc Nephrol 15:119A, 2004
20. SAMUELSSON O, MULEC H, KNIGHT-GIBSON C, et al: Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 12:1908-1915, 1997
21. MUNTNER P, CORESH J, SMITH JC, et al: Plasma lipids and risk of developing renal dysfunction: The atherosclerosis risk in communities study. Kidney Int 58:293-301, 2000
22. SONG Y, LI C, CAI L: Fluvastatin prevents nephropathy likely through suppression of connective tissue growth factor-mediated extracellular matrix accumulation. Exp Mol Pathol 76:66-75, 2004
23. LI C, YANG CW, PARK JH, et al: Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am J Physiol Renal Physiol 286:F46-F57, 2004
24. FRIED LF, ORCHARD TJ, KASISKE BL: Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 59:260-269, 2001
25. BIANCHI S, BIGAZZI R, CAIAZZA A, CAMPESE VM: A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41:565-570, 2003
26. HEART PROTECTION STUDY COLLABORATIVE GROUP:. Lancet 360:7-22, 2002
27. TONELLI M, ISLES C, CURHAN GC, et al: Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110:1557-1563, 2004
28. ASTOR BC, MUNTNER P, LEVIN A, et al: Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (1988-1994). Arch Int Med 162:1401-1408, 2002
29. HAYASHI T, SUZUKI A, SHOJI T, et al: Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 35:250-256, 2000
30. BESARAB A, BOLTON WK, BROWNE JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. New Engl J Med 339:584-590, 1998
31. FURULAND H, LINDE T, AHLMEN J, et al: A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 18:353-361, 2003
32. ROGER SD, MCMAHON LP, CLARKSON A, et al: Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): Results of a randomized clinical trial. J Am Soc Nephrol 15:148-156, 2004
33. LOCATELLI F, ALJAMA P, BARANY P, et al: Revised European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 19:1029-1346, 2004
34. KURIYAMA S, TOMONARI H, YOSHIDA H, et al: Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77:176-185, 1997
35. JUNGERS P, CHOUKROUN G, OUALIM Z, et al: Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 16:307-312, 2001
36. GOUVA C, NIKOLOPOULOS P, IOANNIDIS JPA, et al: Treating anemia early in renal failure patients slows the decline of renal function: A randomised controlled trial. Kidney Int 66:753-760, 2004
37. BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, et al: Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31:607-617, 1998
38. BLOCK GA, KLASSEN PS, LAZARUS JM, et al: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208-2218, 2004
39. BIESENBACH G, JANKO O, ZAZGORNIK J: Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus. Nephrol Dial Transplant 9:1097-1102, 1994
40. REGALADO M, YANG S, WESSON DE: Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension. Am J Kidney Dis 35:687-694, 2000
41. MCLAUGHLIN K, MANNS B, CULLETON B, et al: An economic evaluation of early versus late referral of patients with progressive renal insufficiency. Am J Kidney Dis 38:1122-1128, 2001